Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Recipharm and Pharmanest Form Collaboration

Published: Friday, July 04, 2014
Last Updated: Friday, July 04, 2014
Bookmark and Share
New pharmaceutical manufacturing contract for commercial manufacture and supply of SHACT.

Recipharm Karlskoga AB and Pharmanest AB have announced the formation of a new pharmaceutical manufacturing contract for SHACT.

Every year, millions of women around the world experience pain and discomfort during IUD insertion (intrauterine contraception). There are few treatment options with proven efficacy and safety available to these women.

SHACT is a product based on an innovative formulation of lidocaine, a well-known anesthetic, and a proprietary application device developed to simplify topical application in the cervix and uterus.

SHACT has demonstrated convincing Phase II efficacy data as local anesthesia in connection with IUD insertion and also recently reported positive data from a hysteroscopy study.

Recipharm and Pharmanest have reached a milestone in their existing collaboration and Pharmanest is now preparing its candidate SHACT for launch.

Additionally, the companies have reached a long term agreement for commercial manufacturing, with the precise product launch date to be announced later.

Jointly, the two companies will offer commercial supply to any market that Pharmanest determine to enter for supply and sales of their first pharmaceutical product SHACT.

Ingela Palmkvist, General Manager at Recipharm in Karlskoga, commented: “I really look forward to closely following the introduction of this product to various markets. Indeed, I believe it will make a highly significant difference to patients.”

Gunilla Lundmark, CEO at Pharmanest said: “I am very pleased that Pharmanest and Recipharm have entered into this new collaboration following the product development success achieved to date. Given the strong clinical data we are now rapidly moving toward commercialization. We look forward to working closely with Recipharm for the commercial manufacture of the product and, indeed, to pooling our respective skills and capabilities to supply the pharmaceutical product to key target markets.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Recipharm Signs Agreement with RedHill Biopharma
Agreement for manufacturing of RHB-105 for treatment of H. pylori infection.
Thursday, August 27, 2015
Recipharm Secures Additional Bank Financing for Continued Growth
Company has entered a new five-year SEK 1 500 million term loan facility with three of the largest banks.
Tuesday, July 14, 2015
Recipharm Invests SEK 8 Million in Pharmanest
Investment to support the development of Pharmanest’s lead drug candidate SHACT.
Friday, July 10, 2015
Recipharm Reduces Risk and Improves Compliance with Infor
Company will also help Recipharm continue to improve compliance with the EU-GMP code of practice.
Thursday, July 09, 2015
Recipharm Appoints New Sales Director, Development Services
Amine Tahiri has joined the Development Services Sales team with effect from 1 July 2015.
Tuesday, June 30, 2015
Recipharm Acquires OnTarget Chemistry
Company extends its offering into preclinical development services.
Tuesday, June 16, 2015
Recipharm Appoints Chief Strategy Officer
Company has appointed Jean-François Hilaire to the new position of CSO.
Thursday, June 04, 2015
Recipharm Signs Partnership Agreement with Follicum
Agreement in preparation for a clinical trial of the drug candidate FOL-005.
Thursday, June 04, 2015
Recipharm Appoints New General Manager
Appointment of Giorgio Bruno as General Manager of Recipharm Italia S.p.A.
Thursday, April 30, 2015
Recipharm is Commencing Negotiations with LIDDS
Collaboration on large-scale manufacture of Liproca® Depot.
Friday, April 24, 2015
Recipharm Makes Strategic Investment in Synthonics
Recipharm has purchased $2.0 million of preferred stock in the company.
Wednesday, April 15, 2015
Recipharm and Adroit Science Form Collaboration
Company will support Recipharm’s pharmaceutical development with high quality solid state characterization services.
Thursday, March 26, 2015
Recipharm Completes Korean Serialization Project for Abbott
Validation batches planned to be shipped to Korea mid-March 2015.
Thursday, March 19, 2015
Recipharm Appoints New Position of Vice President Quality Management
Appointment of Thomas Beck with effect from 1st April 2015.
Wednesday, March 11, 2015
Recipharm Presents its Seventh International Environmental Award Winner
Award to Dr Ettore Zuccato for his longstanding work as an outstanding scientist.
Friday, February 27, 2015
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!